CymaBay Therapeutics, Inc.
CBAY · NASDAQ
12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
|---|---|---|---|---|
| Market Cap | $2,677 | $1,576 | $1,119 | $854 |
| - Cash | $207 | $274 | $35 | $59 |
| + Debt | $114 | $104 | $100 | $95 |
| Enterprise Value | $2,585 | $1,407 | $1,183 | $890 |
| Revenue | $0 | $0 | $31 | $0 |
| % Growth | – | -100% | – | – |
| Gross Profit | $0 | -$0 | $31 | -$0 |
| % Margin | 1.8% | – | 99.3% | – |
| EBITDA | -$37 | -$39 | $4 | -$24 |
| % Margin | -64,500% | – | 13% | – |
| Net Income | -$42 | -$34 | -$1 | -$35 |
| % Margin | -73,512.3% | – | -2.6% | – |
| EPS Diluted | -0.37 | -0.32 | -0.008 | -0.36 |
| % Growth | -15.6% | -3,950.6% | 97.8% | – |
| Operating Cash Flow | -$27 | -$26 | -$25 | $6 |
| Capital Expenditures | -$0 | $0 | -$0 | -$0 |
| Free Cash Flow | -$28 | -$26 | -$26 | $6 |